Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Recruiting

I'm Interested

Trial ID: NCT05041309

Purpose

The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored interventional studies.

Official Title

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Stanford Investigator(s)

David Miklos
David Miklos

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Eligibility


Inclusion Criteria:

   - The individual must have received an infusion of gene-modified cells in a completed
   Kite-sponsored parent study, has not withdrawn full consent, and has discontinued or
   completed the post-treatment follow-up period in the parent study, as applicable

   - The individual must understand and voluntarily sign an Informed Consent Form (ICF) or
   an Informed Assent Form prior to any study-related assessments or procedures being
   conducted

   - In the investigator's judgment, the individual is willing and able to complete the
   protocol-required follow-up schedule and comply with the study requirements for
   participation

Exclusion Criteria: none

Intervention(s):

biological: Axicabtagene Ciloleucel

biological: Brexucabtagene Autoleucel

biological: KITE-585

biological: KITE-718

biological: KITE-439

biological: KITE-222

biological: KITE-363

Recruiting

I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kelly Chyan
650-625-8130

New Trial Alerts